Evidence map›Paper›PMID 25277271›Full record

SynthesisEuropean urology2015

A genome-wide pleiotropy scan for prostate cancer risk.

Orestis A Panagiotou, Ruth C Travis, Daniele Campa, Sonja I Berndt, Sara Lindstrom, Peter Kraft, Fredrick R Schumacher, Afshan Siddiq, Stefania I Papatheodorou, Janet L Stanford and 30 more

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 4 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. TERT rs10069690 polymorphism and cancers risk: A meta-analysis.Molecular genetics & genomic medicine · 2019
    Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Cross-Cancer Pleiotropic Associations with Lung Cancer Risk in African Americans.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Article
  10. Article
  11. LncRNAJournal of Cancer · 2018
    Article
  12. Identification of Pleiotropic Cancer Susceptibility Variants from Genome-Wide Association Studies Reveals Functional Characteristics.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Article
  13. A Comparison of High Dimensional Variable Selection Methods with Missing Covariates in a Prostate Cancer Study.Communications in statistics. Case studies, data analysis and applications · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Pleiotropic analysis of cancer risk loci on esophageal adenocarcinoma risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

40 authors at 20 institutions in 12 countries.

Orestis A PanagiotouDivision of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Daniele CampaDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sonja I BerndtDivision of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sara LindstromDepartment of Epidemiology, Harvard School of Public Health, Harvard University, Boston, MA, USA.
Peter KraftDepartment of Epidemiology, Harvard School of Public Health, Harvard University, Boston, MA, USA.
Fredrick R SchumacherDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Afshan SiddiqDepartment of Genomics of Common Disease, School of Public Health, Imperial College London, London, UK.
Stefania I PapatheodorouCyprus International Institute for Environmental and Public Health, Cyprus University of Technology, Limassol, Cyprus.
Janet L StanfordDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Demetrius AlbanesDivision of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jarmo VirtamoDepartment of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland.
Stephanie J WeinsteinDivision of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
W Ryan DiverEpidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
Susan M GapsturEpidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
Victoria L StevensEpidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
Heiner BoeingDepartment of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
H Bas Bueno-de-MesquitaDepartment of Epidemiology and Biostatistics, Imperial College School of Public Health, London, UK; Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands; Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, Netherlands; Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Aurelio Barricarte GurreaNavarre Public Health Institute, Pamplona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Kay-Tee KhawClinical Gerontology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Vittorio KroghEpidemiology and Prevention Unit, Department of Preventive & Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Kim OvervadDepartment of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark.
Elio RiboliDepartment of Epidemiology and Biostatistics, Imperial College School of Public Health, London, UK.
Dimitrios TrichopoulosDepartment of Epidemiology, Harvard School of Public Health, Harvard University, Boston, MA, USA; Hellenic Health Foundation, Athens, Greece; Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece; Department of Nutrition, Harvard School of Public Health, Boston, MA, USA.
Edward GiovannucciDepartment of Epidemiology, Harvard School of Public Health, Harvard University, Boston, MA, USA; Department of Nutrition, Harvard School of Public Health, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Meir StampferDepartment of Epidemiology, Harvard School of Public Health, Harvard University, Boston, MA, USA.
Christopher HaimanDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Brian HendersonDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Loic Le MarchandUniversity of Hawaii Cancer Center, Honolulu, HI, USA.
J Michael GazianoDepartment of Epidemiology, Harvard School of Public Health, Harvard University, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Division of Aging, Brigham and Women's Hospital, Boston, MA, USA.
David J HunterDepartment of Epidemiology, Harvard School of Public Health, Harvard University, Boston, MA, USA; Department of Nutrition, Harvard School of Public Health, Boston, MA, USA.
Stella KoutrosDivision of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Meredith YeagerCore Genotyping Facility Frederick National Laboratory for Cancer Research, Gaithersburg, MD, USA.
Robert N HooverDivision of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
PRACTICAL Consortium
Stephen J ChanockDivision of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Core Genotyping Facility Frederick National Laboratory for Cancer Research, Gaithersburg, MD, USA.
Sholom WacholderDivision of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Timothy J KeyCancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Konstantinos K TsilidisCancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; Department of Hygiene and Epidemiology, University of Ioannina, School of Medicine, Ioannina, Greece. Electronic address: kostas.tsilidis@ceu.ox.ac.uk.
National Institutes of Health · USHarvard University · USAmerican Cancer Society · USUniversity of Southern California · USFrederick National Laboratory for Cancer Research · USGerman Cancer Research Center · DEImperial College London · GBNational Cancer Institute · USUniversity of Ioannina · GRUniversity of Oxford · GBAarhus University · DKAcademy of Athens · GRBrigham and Women's Hospital · USCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESCyprus University of Technology · CYFinnish Institute for Health and Welfare · FIFondazione IRCCS Istituto Nazionale dei Tumori · ITFred Hutch Cancer Center · USGerman Institute of Human Nutrition · DEUniversity Medical Center Utrecht · NL

Funding

Southern Community Cohort StudyR01CA092447 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLOT, WILLIAM J., ZHENG, WEI · 2001 to 2015
$74.0M
Methods for Epidemiology StudiesZIACP010181 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBERT, PAUL · 2009 to 2025
$34.8M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098758 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2003 to 2010
$11.0M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098233 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNTER, DAVID JOHN · 2003 to 2010
$10.8M
Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6M
Epidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4M
Ovarian cancer GWAS discovery, expansion and replication (N2 - Project #1)U19CA148112 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2010 to 2014
$10.2M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098216 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI RIBOLI, ELIO · 2003 to 2011
$7.4M
A genome-wide association study for breast cancer in BRCA1 mutation carriersR01CA128978 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2008 to 2012
$4.8M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3.U01CA098710 · NCI · AMERICAN CANCER SOCIETY, INC. · PI GAPSTUR, SUSAN M · 2003 to 2011
$4.2M
Cancer Research UK 14136Cancer Research UK 15007Cancer Research UK 16491Cancer Research UK 17528Cancer Research UK 19170Cancer Research UK C12292/A11174Cancer Research UK C1281/A12014Cancer Research UK C1287/A10118Cancer Research UK C1287/A 10710Cancer Research UK C16913/A6135Cancer Research UK C5047/A10692Cancer Research UK C5047/A15007Cancer Research UK C5047/A3354Cancer Research UK C5047/A8384CIHR 223175CIHR C5047/A7357Medical Research Council G0401527Medical Research Council G1000143NCI NIH HHS 1U19 CA148065NCI NIH HHS 1U19 CA148112NCI NIH HHS 1U19 CA148537NCI NIH HHS 1 U19 CA 148537-01NCI NIH HHS CA128978NCI NIH HHS R01 CA092447NCI NIH HHS U01 CA098216NCI NIH HHS U01 CA098233NCI NIH HHS U01 CA098710NCI NIH HHS U01 CA098758NCI NIH HHS U01-CA98216-06NCI NIH HHS U01-CA98233-07NCI NIH HHS U01-CA98710-06NCI NIH HHS U01-CA98758-07
6 · The paper itself

Abstract

backgroundNo single-nucleotide polymorphisms (SNPs) specific for aggressive prostate cancer have been identified in genome-wide association studies (GWAS).

objectiveTo test if SNPs associated with other traits may also affect the risk of aggressive prostate cancer. DESIGN, SETTING, AND

participantsSNPs implicated in any phenotype other than prostate cancer (p≤10(-7)) were identified through the catalog of published GWAS and tested in 2891 aggressive prostate cancer cases and 4592 controls from the Breast and Prostate Cancer Cohort Consortium (BPC3). The 40 most significant SNPs were followed up in 4872 aggressive prostate cancer cases and 24,534 controls from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Odds ratios (ORs) and 95% confidence intervals (CIs) for aggressive prostate cancer were estimated. RESULTS AND LIMITATIONS: A total of 4666 SNPs were evaluated by the BPC3. Two signals were seen in regions already reported for prostate cancer risk. rs7014346 at 8q24.21 was marginally associated with aggressive prostate cancer in the BPC3 trial (p=1.6×10(-6)), whereas after meta-analysis by PRACTICAL the summary OR was 1.21 (95% CI 1.16-1.27; p=3.22×10(-18)). rs9900242 at 17q24.3 was also marginally associated with aggressive disease in the meta-analysis (OR 0.90, 95% CI 0.86-0.94; p=2.5×10(-6)). Neither of these SNPs remained statistically significant when conditioning on correlated known prostate cancer SNPs. The meta-analysis by BPC3 and PRACTICAL identified a third promising signal, marked by rs16844874 at 2q34, independent of known prostate cancer loci (OR 1.12, 95% CI 1.06-1.19; p=4.67×10(-5)); it has been shown that SNPs correlated with this signal affect glycine concentrations. The main limitation is the heterogeneity in the definition of aggressive prostate cancer between BPC3 and PRACTICAL.

conclusionsWe did not identify new SNPs for aggressive prostate cancer. However, rs16844874 may provide preliminary genetic evidence on the role of the glycine pathway in prostate cancer etiology. PATIENT SUMMARY: We evaluated whether genetic variants associated with several traits are linked to the risk of aggressive prostate cancer. No new such variants were identified.

Indexed as

Polymorphism, Single NucleotideDisease ProgressionGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeGlycineHumansMalePrognosisProstatic NeoplasmsRisk FactorsGlycineAggressive prostate cancerGenome-wide association studyGlycinePleiotropySingle-nucleotide polymorphism

Identifiers

PMID25277271
PMCPMC4359641
OpenAlexW2168267238

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.